Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Dose Escalation Trial of CD19 Directed Chimeric Antigen Receptor T Cell Therapy in the Treatment of Relapsed/Refractory B Cell Malignancies

NCT04892277 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT04892277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04892277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Dose Escalation Trial of CD19 Directed Chimeric Antigen Receptor T Cell Therapy in the Treatment of Relapsed/Refractory B Cell Malignancies
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Recruiting
Start date
October 3, 2022
Completion date
March 27, 2040
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent b-cell non-hodgkin lymphoma, recurrent chronic lymphocytic leukemia, recurrent small lymphocytic lymphoma, recurrent transformed chronic lymphocytic leukemia, refractory b-cell non-hodgkin lymphoma, refractory chronic lymphocytic leukemia, refractory small lymphocytic lymphoma, refractory transformed chronic lymphocytic leukemia